blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1856095

EP1856095 - QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  29.06.2012
Database last updated on 31.08.2024
Most recent event   Tooltip18.07.2014Lapse of the patent in a contracting state
New state(s): HU		published on 20.08.2014  [2014/34]
Applicant(s)For all designated states
AstraZeneca AB
151 85 Södertälje / SE
[2007/47]
Inventor(s)01 / HALSALL, Christopher Thomas
AstraZeneca R&D Alderley, Alderley Park
Macclesfield, Cheshire SK10 4TG / GB
02 / HENNEQUIN, Laurent Francois Andre
AstraZeneca, Z.I. La Pompelle Bp 1050
F-51689, Reims, Cedex 2 / FR
03 / PLOWRIGHT, Alleyn Thomas
AstraZeneca R&D Alderley, Alderley Park
Macclesfield, Cheshire SK10 4TG / GB
04 / STOREY, Richard
AstraZeneca, Charter Way
Macclesfield, Cheshire SK10 2NA / GB
05 / LENNON, Kieran
AstraZeneca, Charter Way
Macclesfield, Cheshire SK10 2NA / GB
 [2007/47]
Representative(s)Nelson, Michael Andrew, et al
AstraZeneca AB
Global Intellectual Property
151 85 Sodertalje / SE
[N/P]
Former [2007/47]Nelson, Michael Andrew, et al
AstraZeneca AB, Global Intellectual Property
151 85 Sodertalje / SE
Application number, filing date06709888.924.02.2006
[2007/47]
WO2006GB00656
Priority number, dateGB2005000401826.02.2005         Original published format: GB 0504018
GB2005000665731.03.2005         Original published format: GB 0506657
GB2005002400125.11.2005         Original published format: GB 0524001
[2007/47]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2006090163
Date:31.08.2006
Language:EN
[2006/35]
Type: A1 Application with search report 
No.:EP1856095
Date:21.11.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 31.08.2006 takes the place of the publication of the European patent application.
[2007/47]
Type: B1 Patent specification 
No.:EP1856095
Date:24.08.2011
Language:EN
[2011/34]
Search report(s)International search report - published on:EP31.08.2006
ClassificationIPC:C07D401/12, A61K31/517, A61P35/00
[2007/47]
CPC:
C07D401/12 (EP,KR,US); A61K31/517 (KR); A61P35/00 (EP);
A61P43/00 (EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/47]
Extension statesAL26.09.2007
BA26.09.2007
HR26.09.2007
MK26.09.2007
YU26.09.2007
TitleGerman:CHINAZOLINDERIVATE ALS TYROSINKINASEINHIBITOREN[2007/47]
English:QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS[2007/47]
French:DÉRIVÉS DE QUINAZOLINE SERVANT D'INHIBITEURS DE TYROSINE KINASE[2007/47]
Entry into regional phase26.09.2007National basic fee paid 
26.09.2007Designation fee(s) paid 
26.09.2007Examination fee paid 
Examination procedure05.12.2006Request for preliminary examination filed
International Preliminary Examining Authority: EP
26.09.2007Examination requested  [2007/47]
07.04.2009Despatch of a communication from the examining division (Time limit: M06)
07.10.2009Reply to a communication from the examining division
21.03.2011Communication of intention to grant the patent
14.07.2011Fee for grant paid
14.07.2011Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  07.04.2009
Opposition(s)25.05.2012No opposition filed within time limit [2012/31]
Fees paidRenewal fee
29.02.2008Renewal fee patent year 03
28.03.2008Renewal fee patent year 04
01.03.2010Renewal fee patent year 05
28.02.2011Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU24.02.2006
AT24.08.2011
BE24.08.2011
CY24.08.2011
CZ24.08.2011
DK24.08.2011
EE24.08.2011
FI24.08.2011
LT24.08.2011
LV24.08.2011
PL24.08.2011
RO24.08.2011
SI24.08.2011
SK24.08.2011
BG24.11.2011
GR25.11.2011
IS24.12.2011
PT26.12.2011
IE24.02.2012
LU24.02.2012
MC29.02.2012
[2014/34]
Former [2014/27]AT24.08.2011
BE24.08.2011
CY24.08.2011
CZ24.08.2011
DK24.08.2011
EE24.08.2011
FI24.08.2011
LT24.08.2011
LV24.08.2011
PL24.08.2011
RO24.08.2011
SI24.08.2011
SK24.08.2011
BG24.11.2011
GR25.11.2011
IS24.12.2011
PT26.12.2011
IE24.02.2012
LU24.02.2012
MC29.02.2012
Former [2013/29]AT24.08.2011
BE24.08.2011
CY24.08.2011
CZ24.08.2011
DK24.08.2011
EE24.08.2011
FI24.08.2011
LT24.08.2011
LV24.08.2011
PL24.08.2011
RO24.08.2011
SI24.08.2011
SK24.08.2011
BG24.11.2011
GR25.11.2011
IS24.12.2011
PT26.12.2011
IE24.02.2012
MC29.02.2012
Former [2013/08]AT24.08.2011
BE24.08.2011
CY24.08.2011
CZ24.08.2011
DK24.08.2011
EE24.08.2011
FI24.08.2011
LT24.08.2011
LV24.08.2011
PL24.08.2011
RO24.08.2011
SI24.08.2011
SK24.08.2011
GR25.11.2011
IS24.12.2011
PT26.12.2011
IE24.02.2012
MC29.02.2012
Former [2012/42]AT24.08.2011
BE24.08.2011
CY24.08.2011
CZ24.08.2011
DK24.08.2011
EE24.08.2011
FI24.08.2011
LT24.08.2011
LV24.08.2011
PL24.08.2011
RO24.08.2011
SI24.08.2011
SK24.08.2011
GR25.11.2011
IS24.12.2011
PT26.12.2011
MC29.02.2012
Former [2012/33]AT24.08.2011
BE24.08.2011
CY24.08.2011
CZ24.08.2011
DK24.08.2011
EE24.08.2011
FI24.08.2011
LT24.08.2011
LV24.08.2011
PL24.08.2011
RO24.08.2011
SI24.08.2011
SK24.08.2011
GR25.11.2011
IS24.12.2011
PT26.12.2011
Former [2012/23]AT24.08.2011
BE24.08.2011
CY24.08.2011
CZ24.08.2011
EE24.08.2011
FI24.08.2011
LT24.08.2011
LV24.08.2011
PL24.08.2011
RO24.08.2011
SI24.08.2011
SK24.08.2011
GR25.11.2011
IS24.12.2011
PT26.12.2011
Former [2012/21]AT24.08.2011
BE24.08.2011
CY24.08.2011
CZ24.08.2011
FI24.08.2011
LT24.08.2011
LV24.08.2011
PL24.08.2011
SI24.08.2011
GR25.11.2011
IS24.12.2011
PT26.12.2011
Former [2012/17]AT24.08.2011
BE24.08.2011
CY24.08.2011
FI24.08.2011
LT24.08.2011
LV24.08.2011
PL24.08.2011
SI24.08.2011
GR25.11.2011
IS24.12.2011
PT26.12.2011
Former [2012/12]AT24.08.2011
CY24.08.2011
FI24.08.2011
LT24.08.2011
LV24.08.2011
PL24.08.2011
SI24.08.2011
GR25.11.2011
IS24.12.2011
PT26.12.2011
Former [2012/11]AT24.08.2011
FI24.08.2011
LT24.08.2011
LV24.08.2011
PL24.08.2011
SI24.08.2011
GR25.11.2011
IS24.12.2011
PT26.12.2011
Former [2012/10]FI24.08.2011
LT24.08.2011
GR25.11.2011
IS24.12.2011
PT26.12.2011
Former [2012/09]FI24.08.2011
LT24.08.2011
IS24.12.2011
PT26.12.2011
Former [2012/08]LT24.08.2011
IS24.12.2011
Cited inInternational search[DX]WO03082831  (ASTRAZENECA AB [SE], et al) [DX] 1-24 * page 4, line 32 - page 5, line 6 * * examples 2,4,24,25,46 * * claim 1 *;
 [DA]WO03082290  (BOEHRINGER INGELHEIM PHARMA [DE], et al) [DA] 1-24 * page 1, lines 5-16 * * claim 1 *;
 [A]WO2005012290  (ASTRAZENECA AB [SE], et al) [A] 1-24* claim 1 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.